SIRT2 and acute myeloid leukemia: However, our research findings have validated that the co‐administration of VS‐5584 and the SIRT2 inhibitor SirReal2 effectively suppresses the proliferation of AML cells in vitro, in contrast to the administration of VS‐5584 alone.